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ABSTRACT
Ibuprofen is a common Non-Steroidal Anti-Inflammatory Drug (NSAID) sold as a
racemic or equal mixture of (R) and (S) mirror-image enantiomers. Without patent
protection, ibuprofen is an orphan drug even though one enantiomer, (S)-ibuprofen,
provides relief three times faster than its racemic mixture with fewer side effects. The
goal of this research was to develop a facile, environmentally benign (no waste of
ibuprofen or catalysts), and inexpensive process to convert a commercially available
racemic mixture of ibuprofen to the therapeutically active (S)-ibuprofen.
After many attempts, the most successful conversion of racemic ibuprofen to (S)ibuprofen was the in situ racemization and enantioselective hydrolysis (a dynamic kinetic
resolution) of the methyl ester of racemic ibuprofen in the presence of Candida rugosa
lipase and 20 % DMSO at pH 9.8. All reactions started with quantitative extraction of
ibuprofen from inexpensive commercial pills.

Both esters could be quantitatively

isolated after Fischer esterification of racemic ibuprofen with the corresponding alcohol.
The kinetics of the dynamic kinetic resolution of the racemic methyl ibuprofen
ester to (S)-ibuprofen were fit to a “consecutive reactions with a reversible step” model
to give 0.02583 ± 0.0042 and 0.05253 ± 0.00454 h-1 rate constants for the racemization
and hydrolysis steps, respectively. The hydrolysis under these conditions was twice as
slow as most hydrolyses where no racemization was occurring. After 144 hours, 94 % of
racemic ibuprofen by weight was converted to (S)-ibuprofen with an ee of 94 %.

vi

To complete the purification, racemic ibuprofen was crystallized in methanol from
the enriched product of the dynamic kinetic resolution to isolate (S)-ibuprofen in a 93.2
% yield and an ee of 99.7 %. Combining the dynamic kinetic resolution and
crystallization steps, and considering that isolation of ibuprofen from pills and forming its
racemic methyl ester is also quantitative, the overall conversion of (S)-ibuprofen from
racemic ibuprofen pills, is 88 %, with the possibility of recovering all other reagents.
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CHAPTER I
INTRODUCTION
Ibuprofen, acetaminophen and aspirin are some of the most commonly used overthe-counter analgesics. Ibuprofen is the active ingredient in the brand name drugs Advil,
Medipren, Motrin, Nuprin, PediaCare Fever, and Midiron. Ibuprofen belongs to the group
of profen drugs that consist of propionic acids bearing various substituted aromatic
groups at the 2-position, also named α-Arylpropanoic acids. All the α-Arylpropanoic
acids possess a chiral center and are an important class of Non-Steroidal AntiInflammatory Drugs (NSAID) that exist as (R)- and (S)-enantiomers, which have been
used for at least 3 decades. [1] The therapeutic efficacy of this class of drugs is well
demonstrated by the introduction and extensive use of more than a dozen compounds
exemplified by Ibuprofen, Naproxen, Ketoprofen and Flurbiprofen, to mention just a few,
Figure 1.1.
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Figure 1.1. Chemical Structures of Racemic Ibuprofen, Naproxen, Ketoprofen and Flurbiprofen
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Synthesis of ibuprofen was patented (U.S. Patent 3,385,886) by Boots Company
PLC of Nottingham in the 1960s and became available on the drugstore shelves without
prescription in the UK on May 1984 due to its patent expiration. Prior to its introduction,
non-prescription pain relief was mainly provided by acetaminophen (introduced in 1955)
and aspirin (marketed since 1899). [2] It was the first new over-the counter pain-relief
medication to enter the marketplace in a generation. In spite of the 50 years since its
discovery, its industrial preparation remains essentially the same, Scheme 1.1.

O
C

O

O

C

C

O

CH3

Cl
Al
Cl

Cl

Na

O
O

O
Cl

CH

C
C
H2

CH

O

ethyl 2-chloroacetate

CH3

O

H 2O

H

C

O

CH
O
C

H2NOH

CH3

OH
N

H

C
CH

CH3

N
C
CH
CH3

O
C

OH

CH
CH3

Scheme 1.1 Traditional Synthesis of Racemic Ibuprofen
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Ibuprofen is commercially available as a racemic mixture (an equal mixture of (R)
and (S)-enantiomers) and is commonly used for the treatment of rheumatoid arthritis.
Gastrointestinal ulceration and hemorrhage are the most frequent side effects associated
with the profen consumption. The (R)-enantiomer is often the major cause of side
effects. [3] The biological activity of these compounds is known to reside almost
exclusively in the (S)-enantiomer [4 and 5] as it has been demonstrated to be 100 times
more active than (R)-ibuprofen. [6]

Recently, the development of new techniques to

separate or enrich the single (S)-enantiomer of ibuprofen have been claimed.
As non-super imposable mirror images, enantiomers of a racemic mixture have
identical properties in a symmetric environment, but different properties in an
asymmetric or chiral environment such as biological systems.

It is common that

enantiomers have different therapeutic effects, potency, pharmacological activity and
pharmacokinetic profiles since the receptors with which they interact in a biological
system are also chiral. Within biological systems, the metabolism of one enantiomer may
be via a different pathway or occur at a different rate from that of the other enantiomer.
The enantiomers from a racemic mixture may have nearly identical qualitative
pharmacological activity, but quantitatively different potency. [7]
Thalidomide is the most common example as to the importance of realizing the
different therapeutic effects of enantiomers.

Thalidomide is a chiral molecule, its

racemic mixture, Figure 1.2, was prescribed as a sedative and to prevent morning
sickness in pregnancy during the late 1950’s and the earlier 1960’s in almost 50 countries
including West Germany and Britain, where it became popular. In the mid 1960’s it was
3

realized that the drug causes congenital disorders; when taken in early pregnancy. About
20% of fetus presented phocomelia (defective development of the limbs) and other
deformities. 5000 to 10000 such babies were born. It was reported that (R)-Thalidomide
was the effective enantiomer against morning sickness and that the (S)-enantiomer was
the cause of the tetarogenic effects. Although it is an important starting point in the
discussion of the different biological activity of enantiomers, which led to legislation, the
fact that Thalidomide enantiomers have been demonstrated to easily interconvert or
racemize under physiological conditions [8 and 9], it is doubtful that administering only
the (R)-enantiomer would have avoided the Thalidomide tragedy.

Figure 1. 2. Thalidomide Enatiomers

Recently the interest of pharmacological and toxicology activity of the
enantiomers of chiral drugs has been increasing. This interest in drug stereochemistry has
resulted from the considerable advances in the synthesis, analysis and separation of chiral
molecules, together with an increased appreciation of the potential significance of the
different biological properties of the chiral drugs administered as racemates. Thus, the
sale of pure enantiomers has gained full acceptance as shown by the substantial number
of single isomer pharmaceuticals. [10 and 11]
4

The motivation for this single isomer

trend has been provided in part by the FDA (Food and Drug Administration) and in part
by the production of a host of single enantiomer pharmaceuticals previously protected as
racemic mixtures by patents that may last around 20 years. FDA requirements include:
• pharmacological properties of the individual enantiomers and of the racemic
mixture
• assays which determine enantiomeric purity
• the need to produce as single isomer
• economic incentives to develop separation methods for existing racemic mixtures

Those particular chiral drugs, whose patents are expiring, are attracting a
multitude of oversea producers. This would provide pricing competition and increase the
“generic brand” availability from producers with large scale capacities. [12] Today exist
a considerable number of drugs, which are eligible for a racemic to single enantiomer
switch as shown in Table 1.1.

In the last years several racemic mixtures have been

reformulated in to their respective single enantiomer drugs that are now on the market.
This is a method used by companies to extend a patent for several years.
As an example of a racemic switch, omeprazole is a proton pump inhibitor that
blocks the enzyme in the wall of the stomach that produces acid. This drug was patented
by AstraZeneca on 1989 under the names Losec® or Prilosec®. Omeprazole contains a
tricoordinated sulfur atom in a pyramidal structure and therefore can exist in equal
amounts of both the (S)- and (R)-enantiomers, Figure 1.3. [13]

5

Table 1.1. Candidates for Racemic to Single Enantiomer Switch.

[14]

A study demonstrated that the treatment with (S)-omeprazole (esomeprazole)
resulted in higher values in the blood of the two main metabolites (5-hydroxy and
sulphone) than with either (R)-omeprazole or racemic omeprazole after both single and
repeated doses due to a lower metabolic rate of (R)-omeprazole than (S)-omeprazole and,
consequently, racemic omeprazole. Since February of 2001, AstraZeneca marketed the
enantiopure (S)-omeprazole as Nexium®. AztraZeneca patented Nexium® just a few
months before the expiration of the patent of the racemic mixture, Prilosec®.
6

Figure 1.3. (R,S)-Omeprasole Enantiomers

Albuterol or salbutamol is a short acting β2-adrenergic receptor agonist, "first
choice" or preferred as a treatment for both the relief of acute symptoms and the
prevention of exercised-induced bronchial spasms. [15]

This compound was marketed

in 1968 by Allen & Hanburys under the brand name Ventolin®. It has been established
that the bronchodilating effect resides with the (R)-albuterol enantiomer and the
nonactive enantiomer is (S)-albuterol, these are referred to as the eutomer (the active
enantiomer) and distomer (the less active enantiomer), respectively, Figure 1.4. [16]
There are several reports indicating that (S)-albuterol induces airway hyperreactivity and
may cause adverse effects in asthmatics possibly leading to fatalities. (R)-Albuterol
inhibits histamine release from human basophils whereas (S)-albuterol may increase
histamine release. [17] This difference in metabolic rate of sulfation and elimination
when the racemate is given may result in accumulation of (S)-albuterol and subsequent
increased bronchial reactivity without bronchodilatary protection. Today enantiopure (R)albuterol can be purchased by prescription. It was released by Sepracor Inc. on January
of 2002 under the commercial name Xopenex®. Some studies demonstrated that there is
7

no enhancement of activity on (R)-albuterol than the racemic mixture but it was
demonstrated that side effects including tachycardia, tremors, and nervousness can be
avoided by taking just the (R)-enantiomer.

Figure 1.4 . (R,S)-Albuterol Enantiomers

Another example is the histamine H1-receptor antagonist cetirizine (Zyrtec®).
Zyrtec is the racemic mixture of levocetirizine and dextrocetirizine, Figure 1.5. This
commercial drug is used in patients with urticaria and allergic rhinitis. Optically pure
cetirizines show different pharmacological effects. Dextrocetirizine is more useful for the
treatment of urticaria and levocetirizine is more useful for the treatment of allergic
disorders while avoiding the adverse effects associated with the racemic mixture of
cetirizine. [18] The reason of the pharmacological difference is not known yet. In
Europe and the USA, the desired enantiomer for treatment of allergies is now available
under the trademark Xyzal®. Some studies have demonstrated that Xyzal is up to 4 times
more potent than the racemic mixture.

Side effects such as dry mouth, wheezing,

8

coughing, urticarial eruptions, and hypersensitivity are diminished substantially when the
pure enantiomer is administered.

Figure 1.5. (R,S)-Cetirizine Enantiomers

Enantiopure drugs represent a large share of the pharmaceutical market. Global
revenues from chiral technologies soared from $6.63 billion in 2000 to $16.03 billion in
2007, growing at a compound annual rate of 13.4% during that period. Approximately
80% of all products currently in development for the pharmaceutical industry are based
on chiral building blocks. [19] Below, Table 1.2 outlines the top ten drugs sold in the
United States during 2008, all of which are chiral.
In the last 2 decades, the synthesis and/or separation of chiral drugs and their
intermediates have received much attention. Besides synthesizing chiral drugs from
natural chiral building blocks (e.g., carbohydrates and amino acids) or chiral auxiliaries,
the most common procedures for enantiomer separation are formation of diasteromeric
salts of chiral amines or carboxylic acids and crystallization, chiral chromatography,
enzymatic catalytic resolution (kinetic resolution), and lately by dynamic kinetic
resolution. [20, 21, 22 and 23]

9

Table 1.2 Top Ten of Chiral Drug Sales in 2008

Due to its operational simplicity the majority of industrial scale syntheses, employ
a kinetic resolution via enantioselective enzymatic reactions to separate the desired
enantiomer from the racemic mixture. [24]

However, this methodology has the inherent

disadvantage of limiting the yield to a maximum of 50%, which can have an impact on
the environment and on the economic viability of the procedure due to the production of
50% waste. [25]
The disadvantage of a maximum 50% yield of the desire enantiomer and a 50 %
yield of “waste” has lead to the work described in this dissertation on the racemization or
conversion of the undesired enantiomer to the desired enantiomer, in the case of
ibuprofen, in-situ conversion of (R)-ibuprofen to (S)-ibuprofen. This conversion has been
previously attempted by many methods.
10

One approach involved the enzymatic resolution of ibuprofen enantiomers,
separation of (S)-ibuprofen, followed by brute force racemization of (R)-ibuprofen by at
least an 8 hour reflux in a 1:1 solution of dimethylsulfoxide (DMSO) and 2 M NaOH.
These harsh reaction conditions are required to deprotonate the α-position of a
carboxylate salt to form a planar double enolate intermediate. This method is inefficient
by requiring the geometric repetition of the resolution and racemization steps until
“enough” (S)-ibuprofen has been produced and by the complexity of the experiments for
an industrial scale. [26]
Other research groups have attempted to produce pure (S)-profens by enzymatic
hydrolysis of the racemic mixture of their trifluoroethyl thioesters (such as that of
naproxen and suprofen) with in situ racemization catalyzed by organic bases. Up to this
point, the resulting (S)-profens were produced in low conversion and with low
enantiomeric purity because the bases can also hydrolyze the esters to profens without
enantioselectivity. Besides the expense and complexity of reagents that mimic in vivo
sulfur containing isomerases, the other major limitation of these reactions is that the
enzyme must be encapsulated to avoid degrading it under harsh pH conditions. [27 and
28]
This dissertation describes several attempts and eventual success to overcome the
50 % yield limitation of traditional kinetic resolutions by in situ racemization. These
techniques are referred to as dynamic kinetic resolutions. The goal of this research was to
develop a facile, environmentally benign (no waste of ibuprofen or catalysts), and
11

inexpensive process to convert a commercially available racemic mixture of ibuprofen to
the therapeutically active (S)-ibuprofen.
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CHAPTER 2
RESULTS
After initial isolation from commercial pills, racemic ibuprofen was converted to
racemic ibuprofen esters under different conditions.

The esters were subjected to

different pHs and solvent conditions in the presence of Candida rugosa lipase to induce
in situ racemization and enantioselective hydrolysis, converting most of the racemic
ibuprofen to (S)-ibuprofen in high enantiomeric excess. Pure (S)-ibuprofen was isolated
in high yield. Other attempts to convert racemic ibuprofen to pure (S)-ibuprofen are also
briefly described.
2.1 Ibuprofen Extraction
Ibuprofen was extracted with acetone from commercial ibuprofen tablets (200
mg/pill Member’s Mark) because it was readily available, inexpensive ($12 per gram
Aldrich, 5 ¢ per gram Sam’s Club) and of the quality available to the consumer. The
active ingredient (ibuprofen) was quantified to be on average as advertised. For example,
5.964 g of ibuprofen were isolated from 30 200 mg pills, a 99.4 % recovery, Figure 2.1.
Chiral HPLC was used to analytically separate enantiomers and to verify the racemic
composition of ibuprofen.
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Figure 2.1 Commercial Ibuprofen Tablets, Extracted Ibuprofen and Racemic Ibuprofen Chiral HPLC
Chromatograph

2.2.1 Racemic Ibuprofen Esters Synthesis
Initially, the methyl ester of racemic ibuprofen was synthesized from the acid
chloride of ibuprofen, Figure 2.2. Thionyl chloride and racemic ibuprofen were reacted
to produce the acid chloride followed by evaporation of excess thionyl chloride. The
resultant acid chloride was reacted with methanol producing the methyl ester, which was
isolated by extraction with dichloromethane and solvent evaporation to give a 93 % yield.

Figure 2.2. Traditional Racemic Ibuprofen Ester Synthesis
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In order to avoid the caustic conditions of the acid chloride route, the racemic
ibuprofen esters were also synthesized by Fischer esterification. For all the reactions,
into a 100 mL round bottom flask was added 10 mmol of racemic ibuprofen, 0.5 mL of
concentrated H2SO4 and 40 mL of different alcohols. The reactions were stirred at 40 °C
for 5 hours and were monitored by chiral HPLC.
Each ester required a different purification method.

In the methyl ester case,

hexanes extraction was sufficient to purify the product because methanol is insoluble in
this solvent. In all other cases, more hexanes (80 mL) and washing with water was
necessary because larger alcohols are amphiphilic or soluble in both polar and non-polar
phases. A rotatory evaporator was used to remove the hexanes and volatile alcohols, and
the purification was completed by bulb-bulb distillation. The isolation of all esters by the
Fischer reaction was quantitative.
Chiral HPLC analysis confirmed that all the esters were pure but only the
enantiomers of the propyl ester were baseline resolved, Figure 2.3. All esters, being less
polar than ibuprofen, eluded closer to the void time, Figure 2.4.

Figure 2.3. Chromatographs of Racemic Methyl, Ethyl and Butyl Ibuprofen Esters Respectively
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Figure 2.4. Chromatograph of Racemic Propyl Ibuprofen Ester

2.2.2 Kinetic Resolution of Racemic Methyl Ibuprofen Ester
Initially in situ racemization of ibuprofen esters was attempted with the methyl
ester under different pH conditions. Though not successful, this was also the method of
separating ibuprofen enantiomers that would be used for further studies.
The methyl ester of racemic ibuprofen was hydrolyzed by Candida rugosa lipase
in a buffered aqueous media at 40 °C and different pH (5.3, 7.2 and 9.8) . The reaction
was monitored at different time intervals. Alkaline samples were acidified with 0.25 M
HCl solution. All samples were extracted with hexanes and analyzed by chiral HPLC.
The enantiomeric excess (ee) of the ibuprofen product was calculated by Equation 2.1.
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ee =

[ S ] − [ R]
= enantiomeric excess of product………..……(2.1)
[ S ] + [ R]

The percent composition of each compound, was calculated directly from the
chiral HPLC spectral areas, since the molar absorptivity of (R)-ibuprofen, (S)-ibuprofen
and the ester products are equal because phenyl is the major chromophore at the 256 nm
wavelength of the UV detector. [32]
The Enantiomeric Ratio (E) describes how well the enzyme discriminates between
the enantiomers of a substance under given reaction conditions as given in Equation 2.2,
where conversion (c) was determined by Equation 2.3 and ee is the enantiomeric excess
of the product in decimal form.

E = ln[(1 − c)(1 − ee)] / ln[(1 − c)(1 + ee)] ……………………….(2.2)

c = 1−

[ S ester ] + [ Rester ]
= Conversion……………….………(2.3)
[ S ester ]0 + [ Rester ]0

At all pHs, mostly the (S)-ibuprofen ester was hydrolyzed to (S)-ibuprofen and no
major in situ racemization was observed, Scheme 2.1. Though this hydrolysis reaction
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involves two substrates, water and the racemic methyl ibuprofen ester, because water is
in excess, the reactions behaved like a single substrate mechanism and look linear (time
is proportional to the conversion), Figure 2.5. Statistically the differences in the rate and
the enantioselectivities (E) of the reactions at different pHs were not significant, Table
2.1.
S-ester
+ Water

Candida rugosa Lipase

R-ester

S-acid + R-ester + R-alcohol

Scheme 2.1 Kinetic Resolution of Racemic Ibuprofen Ester

Figure 2.5. Enzymatic Enantioselective Hydrolysis of Racemic Ibuprofen at Different pH

For the hydrolysis of the racemic methyl ibuprofen ester at different pHs, E values
are given in Table 2.1. Although several studies of the kinetics of Candida rugosa lipase
reactions have been carried out [33 and 34], the most common procedure is the use of the
pseudo-first order model [35]. Due to the high enantioselectivity in other and this
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ibuprofen ester hydrolysis reactions [36], it can be assumed that only the (S)-methyl
ibuprofen ester was hydrolyzed.
Under this hypothesis, using data from Table 2.1, different kinetics were tested,
and the hydrolysis of the racemic methyl ibuprofen ester under the optimal conditions (40
ºC, barometric pressure and stirring magnet agitation) was fitted to first-order kinetics,
time versus ln[(S)-ibuprofen], Figure 2.6.

Table 2.1. Time, Conversion and Enantiomeric Excess Values for the Kinetic Resolutions at Different pH
KR at pH 5.3
KR at pH 7.2
KR at pH 9.8
Time
Conversion
ee
E
Time
Conversion
ee
E
Time
Conversion
ee
E
0
0
0
0
0
0
6
16.254
97.6
5
6
20.648
99.2
6
6
18.579
94.4
5
13
36.768
94.5 13
13
40.261
98.6 17
13
39.515
96.8 19
14
40.912
94.2 19
14
42.908
98.3 32
14
43.474
97.9 34
16
42.932
93.8 25
16
42.974
97.5 36
16
46.013
96.7 50
24
45.276
93.8 36
24
45.285
95.8 40
24
46.200
96.6 52
36
46.573
93.7 49
36
46.564
95.5 54

The hydrolysis reaction for racemic methyl ibuprofen ester at pH 9.8 is properly
described by pseudo-first order kinetics, Equation 2.4 and Equation 2.5, as indicated by
a linear least-squares fit with goodness of fit R2 = 0.9753. The pseudo first-order rate
constant (k) was found to be 0.0975 ± .0012h-1 from the slope of the fit, Equation 2.6.

− d [( S ) − Ibuprofen] / dt = k[( S ) − Ester ]To ………………………..(2.4)
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ln[(S ) − Ibuprofen]Tx = −kt + ln[(S ) − Ester ]To ………………………(2.5)

y = 0.0961x + 2.3725 …………….………………..(2.6)

Figure 2.6 Determination of the Pseudo-First-Order-Kinetic

2.2.3 Addition of DMSO as Co-Solvent to Increase the Enantioselectivity of Candida
rugosa Lipase
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The addition of ionic liquids such as DMSO has been reported to enhance the
enantioselectivity of Candida rugosa lipase towards hydrolysis of chiral esters. [37] The
addition of polar compounds can change the lipase conformation from the less
hydrophobic closed form to a more hydrophobic open form favoring the binding of the
hydrophobic substrate to the active site of the enzyme, Figure 2.7. [38] This enhanced
enantioselectivity has been confirmed for ibuprofen by adding DMSO (20 % volume) to
the previously described hydrolysis reactions under neutral conditions. For example,
after 45 % conversion, the ee of ibuprofen obtained was 98 % versus 96 %, with and
without DMSO added, respectively (Figure 2.8) without decreasing the general reactivity
of the enzyme.

Figure 2.7. Open Structure of Candida rugosa Lipase. [39]
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Figure 2.8. HPLC Chromatogram of Enzymatic Racemic Ibuprofen Hydrolysis at pH 7.2 without (ee = 95.5)
and with DMSO Addition Respectively

Following the observation that the activity of Candida rugosa lipase is not greatly
affected by pH or DMSO in an aqueous buffer, and knowing that DMSO has been used
to catalyze the brute force racemization of ibuprofen under highly alkaline conditions,
[26] it was hypothesize that DMSO might allow the racemization of ibuprofen esters
under mild alkaline conditions because enolization of esters only requires one
deprotonation as opposed to the two deprotonations required for racemization of
ibuprofen, Scheme 2.2.

It was hypothesized that DMSO might allow racemization

because it allows non-polar compounds to better dissolve in an aqueous media.

H3C

H

H
OH

O

CH3

O

HO-, Slow

OH

Fast
O

Fast

HO-, Slow

O

Scheme 2.2. Brute Force Racemization of (R)-Ibuprofen

The following reactions were performed to test the hypothesis that DMSO can
catalyze racemization of ibuprofen esters under acidic or basic conditions while allowing
enantioselective enzymatic hydrolysis of (S)-ibuprofen esters to (S)-ibuprofen. Coupling
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these two steps together would allow for conversion of racemic ibuprofen to (S)ibuprofen.
2.2.4 Racemization of (R)-Methyl Ibuprofen Esters in Different Buffers pH with
DMSO as Co-Solvent
The (R)-methyl ibuprofen ester was isolated from a previously described
enantioselective enzymatic hydrolysis reaction. The ester was reacted at 40 °C in a 20%
DMSO/buffer solutions at different pHs (5.31, 7.1 and 9.8). The reaction was sampled
every 24 hour for five days. At pH 5.3, acid catalyzed hydrolysis with and without
DMSO over the prolonged reaction period. The production of racemic ibuprofen was
observed, Scheme 2.3 and Figure 2.9.

Scheme 2.3 Acid Hydrolysis of Esters

Figure 2.9. Show the Acid Catalyzed Hydrolysis of (R)-Methyl Ibuprofen Ester
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At pH 7.2, no racemization or hydrolysis reactions occurred with or without
DMSO. At pH 9.8, complete racemization without hydrolysis was observed after 5 days
for the reaction with 20% DMSO, Figure 2.10.

At this pH, no racemization or

hydrolysis occurred without DMSO present. The racemization under basic conditions is
explained by the effective deprotonation at the α-position giving a planar enolate in
DMSO as showed in Scheme 2.4.

Figure 2.10. HPLC Analysis of (R)-Methyl Ibuprofen Ester Racemization, Samples From Day 1, 3, 4 and 5
From Left to Right and Top to Bottom Respectively

Scheme 2.4. Racemization Reaction of the (R)-Methyl Ibuprofen Ester Under Basic Conditions

2.2.5 Racemization of (R)-Ibuprofen at pH 5.3 Buffer
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In order to determine whether racemization occurred to the ibuprofen ester,
ibuprofen or both at pH 5.3, a separated experiment was performed. Enriched (R)ibuprofen with ee of 98.6 % was stirred and heated to 40 C° in a 20 % DMSO/ pH 5.3
aqueous buffer. The reaction was monitored daily for a period of 6 days with no
racemization observed.
2.2.6 Dynamic Kinetic Resolution of Racemic Ibuprofen Esters
The enantioselective enzymatic hydrolysis of the racemic methyl ibuprofen ester
with in situ racemization of the unreacted the (R)-methyl ibuprofen ester was tried at
different pHs (5.3, 7.2 and 9.8) with 20% DMSO by volume as co-solvent and the
respective control reactions (no DMSO), Scheme 2.5. All reactions were stirred at 40 ºC
and monitored at different time intervals by chiral HPLC until the reaction velocity
slowed or conversion stopped.

O

O

CH3

CH3
O

O

O

Candida rugosa Lipase

Na

40 °C
Buffer pH 9.8

-H

+H

O

+H

-H
O

CH3
O

Scheme 2.5. Dynamic Kinetic Resolution of Racemic Methyl Ibuprofen Ester. (Enantioselective Enzymatic
Hydrolysis of Racemic Methyl Ibuprofen Ester in 20% DMSO / pH 9.8)
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Figure 2.11 shows the progress of the dynamic kinetic resolution process at
different pHs. At acidic and neutral pHs, the reaction proceeded up to 45 % conversion
in 24 hours and then stopped asymptotically at 47 %, even after several days. This
confirms the previous observation, that the (R)-methyl ibuprofen ester does not racemize
and that only the (S)-methyl ibuprofen ester is hydrolyzed.

Figure 2.11. Progress of Dynamic Kinetic Resolution Reaction

The reaction at pH 9.8 overcame the 50 % conversion limit, confirming that
racemization is occurring between methyl ibuprofen ester enantiomers, followed by
enantioselective hydrolysis of the (S)-methyl ibuprofen ester, as shown in Table 2.2 and
Figure 2.12.
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Table 2.2. Time, Conversion and Enantiomeric Excess Values for the Kinetic Resolutions at Different pH
DKR at pH 5.3
DKR at pH 7.2
DKR at pH 9.8
Time
Conversion
ee
Time
Conversion
ee
Time
Conversion
ee
0
0
0
0
0
0
6
13.879
95.1
6
19.911
99.1
12
23.568
100.0
13
27.876
93.9
13
38.966
98.4
24
41.524
98.6
14
34.235
89.6
14
40.803
98.3
30
50.468
98.4
16
38.987
88.7
16
41.663
98.3
48
57.56
97.8
24
41.209
86.8
24
43.993
98.2
72
68.562
97.2
36
45.995
87.1
36
45.342
98.1
96
77.358
95.5
48
46.761
86.7
48
46.231
98.0
120
86.598
94.4
144
93.823
94.1

Figure 2.12. HPLC Analysis of (R,S)-Methyl Ibuprofen Ester Hydrolysis with in situ Racemization of the UnReacted (R)-Methyl Ibuprofen Ester on 20% DMSO/Buffer pH 9.8. Sample Order From Left to Right and
Top to Bottom Respectively
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After 5 days, 94 % by weight of the original racemic ibuprofen was isolated by
acidifying the reaction, extraction with hexanes, and evaporation as enantiomerically
enriched (S)-ibuprofen. This represents a 188 % yield of (S)-ibuprofen from the original
amount. The ee of the isolated (S)-ibuprofen was also 94 %.
Due to the high enantioselectivity of Candida rugosa lipase observed in previous
ibuprofen esterification and hydrolysis studies [26], it can be assumed that only the (S)methyl ibuprofen ester was hydrolyzed. Under this hypothesis and the data from Table
2.3 different kinetic models were developed.
Although several studies of the Candida rugosa lipase kinetics have been carried
out [33], the most common procedure is the use of the pseudo-first order model [34 and
35]. According to Figure 2.11, there are two major phases of the dynamic kinetic
resolution as delineated by a discontinuity. The first phase from 0 to 30 hours is when
most of the (S)-methyl ibuprofen ester is being hydrolyzed. Equation 2.7 fits the first
phase of the reaction as shown in Figure 2.13 with an R2 = 0.9929. This implies that the
rate of hydrolysis for this reaction is 0.043 h-1, slower than observed when no
racemization was occurring.

y = 0.043 x + 2.6565. …………….………………..(2.7)
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Figure 2.13. Determination of the Pseudo-First-Order-Kinetic at the First Part of the DKR Reaction

In the second phase of the dynamic kinetic resolution from 30 to 144 hours, most
of the (S)-methyl ibuprofen ester has been hydrolyzed and the kinetics represents mostly
the racemization of the (R)-methyl ibuprofen ester. Equation 2.8 fits this region with
pseudo-first order kinetics and R2 = 0.9921. This implies that the rate of racemization for
this reaction is 0.0044 h-1, a magnitude of order slower than the rate of hydrolysis, Figure
2.14.

y = 0.0044 x + 3.9205 …………….………………..(2.8)
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Figure 2.14. Determination of the Pseudo-First-Order-Kinetic at the Second Part of the DKR Reaction

Unfortunately, the data cannot be fit so simply by pseudo-first order kinetics since
the first phase of the dynamic kinetic resolution does not solely represent the hydrolysis
of the (S)-methyl ibuprofen ester but also the racemization of the ibuprofen ester
enantiomers. A more complete kinetic model is given by Scheme 2.6, a consecutive
reaction with a reversible step, ignoring the enolate intermediate between ester
enantiomers and the complexation of esters with Candida rugosa lipase. k1 and k-1 are
the rates of racemization as before, which are assumed to be equal. K2 is the rate of
hydrolysis. Equation 2.9 represents the rate of formation of the (R)-methyl ibuprofen
ester, Re. Equation 2.10 gives the rate of formation of the (S)-methyl ibuprofen ester, Se.
Equation 2.11 represents the rate of formation of the sodium salt of ibuprofen, Sp.
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Re

k1

Se

k-1

k2

Sp

Scheme 2.6. Consecutive Reaction with a Reversible Step

dRe (t )
= −k1 Re (t ) + k1 S p (t ) ……………………..(2.9)
dt

dS e (t )
= k1 Re (t ) − (k1 + k 2 ) S e (t ) ……………………(2.10)
dt

dS p (t )
dt

= k 2 S e (t ) ………………………………….(2.11)

Maxima software was used to solve these differential equations exactly assuming
that the initial concentrations of Re and Se were 0.5 and zero for Sp. [40] The exact
solutions are given in Equations 2.12 through 2.14, where %e is Maxima’s notation for
exponential base e.

Equation 2.12. Represents the Rate of Formation of the (R)-Methyl Ibuprofen Ester, Re

Equation 2.13. Represents the Rate of Formation of the (S)-Methyl Ibuprofen Ester, Se
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Equation 2.14. Represents the Rate of Formation of the Sodium Salt of Ibuprofen, Sp

These equations were graphed using Microsoft Excel Software, Figure 2.15, and a
macro program to vary k1 and k2 to fit the data in Table 2.3 by the least-squares criterion.
The average k1 and k2 values for three experiments were found to be 0.02583 ± 0.0042
and 0.05253 ± 0.00454 h-1, respectively, indicating that the rate of racemization is only
about half of the rate of hydrolysis.

Figure 2.15. Progress of the Dynamic Kinetic Resolution of Ibuprofen
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In order to test the generality of the developed dynamic kinetic resolution, racemic
propyl ibuprofen ester was synthesized and used in the same reaction. At pH 5.3, the
reaction proceeded up to only 46 % conversion and the ee of the product was 80%. When
the buffer pH was 7.2 the reaction stopped at 46 % conversion with an ee of 82 %.
Finally, for the reaction at pH 9.8 the conversion stopped at 56% with a product ee of
93% after 120 hours, Figure 2.16.

Therefore, the dynamic kinetic resolution is too slow

for larger ibuprofen esters than methyl.

Figure 2.16. Dynamic Kinetic Resolution with Propyl Ibuprofen Ester at pH 9.8

2.2.7 Crystallization of Enriched (S)-Ibuprofen to Enhance the Enantiomeric Excess
Repeated enantioselective reactions is the most common way to increase the
enantiopurity or the enantiomeric excess of the desired product, (S)-ibuprofen in this
case. However, this method requires the used of more time, catalyst, reagents, solvents,
equipment, energy, purifications, and complexity. In order to increase the ee of the
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product of the dynamic kinetic resolution, different crystallization techniques were
attempted.
In separate experiments, 2 g of pulverized enantiomerically enriched (S)-ibuprofen
(ee = 94%), a magnetic stir bar, and 10 mL of anhydrous methanol, ethanol and
isopropanol, respectively, were added to a 25 mL round bottom flask. The flasks were
heated to 45 ºC in a water bath and were stirred until the solutions were clear. Then the
temperature of the water bath was reduced to 35 ºC. When the flasks were cooled,
racemic ibuprofen crystals were added as seed, and the flasks were placed in an ice bath
and kept in a refrigerator for 12 hours. After crystallization occurred for the isopropanol
and ethanol cases, the crystals were filtered and air-dried to give 87 and 76 %,
respectively, of recovered ibuprofen. The crystals were analyzed by chiral HPLC and
were determined to have an ee of 94 to 95 % of (S)-ibuprofen for the isopropanol and
ethanol cases, respectively.
In the case of methanol, the recrystalization solution was only turbid. The solution
was filtered and analyzed by chiral HPLC indicating it had an ee of 99.7 %. The
methanol was evaporated to give (S)-ibuprofen in a 93.2 % yield. The optical rotation of
this material was [α]25D = 59.52 ° (ethanol 95%, c = 1), indicating an ee of at least 99.2
%. The melting point of 55 °C agreed well with the literature value of 55.5 °C. [41]
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2.3 Other In Situ Racemization Attempts
2.3.1 Attempted In Situ Racemization of Ibuprofen with Organic Acids in
Cyclohexane
A series of organic acids (p-toluenesulfonic, p-toluenesulfonyl chloride, phenyl
dimethyl chlorosilane, boric acid, pyruvic acid, isolute Si-propylsulfonic acid, and isolute
Si-TsOH) were added to the reaction of racemic ibuprofen, decan-1-ol, and Candida
rugosa lipase in cyclohexane.

In no case was racemization of ibuprofen observed,

whereas the esterification of (S)-ibuprofen was greatly reduced with concentration of acid
to enzyme greater than 5 % by weight.
2.3.2 Attempted In Situ Racemization of Ibuprofen with Organic Bases in
Cyclohexane
A series of organic bases (tripentylamine, tributylamine, diethylamine,
methyldiethylamine and ethyldisopropylamine) were added to the reaction of racemic
ibuprofen, decan-1-ol, and Candida rugosa lipase in cyclohexane.

In no case was

racemization of ibuprofen observed, whereas the esterification of (S)-ibuprofen was
greatly reduced with concentration of base to enzyme greater than 10 % by weight.
2.3.3 Attempted Racemization of Methyl Ibuprofen Esters with Light
In order to induce the in situ racemization of the racemic methyl ibuprofen ester
with enantioselective hydrolysis of the (S)-methyl ibuprofen ester, a photochemically
allowed 1,3-sigmatropic rearrangement of ester to enol was attempted as shown in
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Figure 2.17, Scheme 2.8. Chiral HPLC analysis, Figure 2.18, showed the development
of several byproducts including one that initially was thought to be an increase of (S)ibuprofen ester. In addition, after several attempts, it was determined that ibuprofen
esters easily evaporate with or without water present.
It is important to note that ibuprofen esters are volatile, easily evaporating if left
out in the open. Ibuprofen esters also generate small amounts of good chromophores
with visible and ultraviolet light exposure that often confused the HPLC analysis of their
reactions. Over prolonged exposure, these esters often turned yellow.

Figure 2.17. Photochemical Reactors

Scheme 2.7. Expected 1,3 Sigmatropic Reaction for the Racemization of (R)-Methyl Ibuprofen Ester
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Figure 2.18. Chromatograph of Photochemical Racemization Attempt

2.3.4 Attempted Racemization of Ibuprofen in a Two-Phase Continuous Reactor
Racemization of racemic ibuprofen was attempted in the presence of Candida
rugosa lipase, methanol, aqueous base, and cyclohexane in the left part of Figure 2.19.
The idea was that any (S)-methyl ester formed would dissolve in cyclohexane and would
be transported to the right receiver flask. The left flask was heated to 40 °C. The right
flask was heated to 60 ºC to recycle the methanol and cyclohexane. The pH of the
aqueous portion was 8.6. Chiral HPLC analysis showed some methyl ester being formed
for the first 8 hours. Thereafter racemic ibuprofen was also transported.
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Figure 2.19. Reactor used for the Conversion of Racemic Ibuprofen to (S)-Ibuprofen

2.3.5 Attempted Racemization of Methyl Ibuprofen Esters with a Three-Phase
Membrane Separated Reactor
To avoid hydrolyzing ibuprofen esters, they were exposed to sodium hydroxide
pouches suspended in cyclohexane. The pouches were made from either filter paper or
Whatman Nucleopore filters.

Enantioselective enzymatic hydrolysis catalyzed by

Candida rugosa lipase was expected to occur below in the aqueous phase as shown in
Figure 2.20. For both pouch types, solid appeared to form on their surface, which
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eventually dropped into the lower aqueous phase to increase the pH. The reactions were
not studies beyond 10 % conversion and 48 hours.

Figure 2.20. Two-Phase Hydrolysis Reaction with Racemization of the Un-Reacted Ester at the Non-Polar
Phase

2.3.6 Attempted Acid Catalyzed Esterification, Racemization and Enantioselective
Hydrolysis in a Two Reactor System
To separate the racemization and enantioselective enzymatic reactions that were
believe to have incompatible environments; racemic ibuprofen, methanol and sulfuric
acid were placed in one flask, and Candida rugosa lipase and an aqueous buffer were
place in a second flask. The flasks were connected by a distillation head and were heated
to 40 °C in the same sand bath/heater. Racemization and ester formation were to occur in
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the left flask, Figure 2.21, while enantioselective hydrolysis was to occur in the right
flask as the methyl ibuprofen ester distilled over. Because of the differences in vapor
pressure of the solvents used, the left flask always overfilled and contaminated the right
flask with acid.

Figure 2.21. Two Reactor System

40

CHAPTER 3
CONCLUSIONS
Though extraction of racemic ibuprofen from commercial pills with inexpensive
acetone is not a traditional way of obtaining laboratory reagents, this step represents a
time and cost effective way of starting this research. Thus the overall conversion of
racemic ibuprofen to (S)-ibuprofen should be overall cost effective, environmentally
benign, and facile.
To avoid generating waste reagents like sulfur dioxide and hydrogen chloride in
the synthesis and use of acid chlorides, the Fischer esterification of ibuprofen was
investigated using sulfuric acid as a reusable catalyst. It was found that most esters could
be generated quantitatively but only the methyl ester was easily separated because
methanol and sulfuric acid are insoluble in the extracting solvent, hexanes. The Fischer
esterification was also less time consuming and easier to run than using thionyl chloride
to make the acid chloride of ibuprofen.
From previous work, Candida rugosa lipase had enatiomeric ratios E of 86 and
130 for esterifications of racemic ibuprofen with butyl and decyl alcohols [24]. Though
operating in the opposite direction, this work confirms that this lipase is less selective
towards hydrolysis of the racemic methyl ibuprofen ester with a maximum E value of 52.
This is believed to be due to the greater interaction between larger esters and the lipase
active site channel. [42] Nevertheless, an E value of 52 is much greater than the
minimum (10) believe to be required to effectively select between enantiomers. [43]
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It is interesting to note that the effect of acids and bases on the activity of Candida
rugosa lipase is much different in aqueous versus non-polar solvents. Whereas the rate
of hydrolysis of racemic methyl ibuprofen esters did not change significantly in acidic,
neutral or basic aqueous buffers; the activity of the lipase toward esterification was
greatly reduced at acid or base concentrations greater than 5 or 10 % by weight
respectively, when added in cyclohexane. This is probably because organic acids and
bases are polar compounds that are more attracted to the lipase in cyclohexane and
denature it. Though no racemization was observed, surprisely, racemic methyl ibuprofen
esters were not hydrolyzed either by aqueous acid or base conditions.
Once DMSO was added, the desired racemization reactions started to be observed
for acidic and basic conditions because of the known ability of ionic liquids to allow
polar and non-polar reagents to mix. At pH 5.3, 14.8 % of the (R)-methyl ibuprofen ester
was hydrolyzed without any lipase present giving ibuprofen with an ee of 12 %. That
(R)-ibuprofen does not racemize under the same reaction conditions demonstrates that it
is the more electron rich ester that is protonated, enolized and undergoes racemization.
Under basic conditions and DMSO present, in situ racemization of racemic
ibuprofen esters was observed along with the hydrolysis of the (S)-methyl ibuprofen ester
to (S)-ibuprofen in a 94 % conversion by weight of original ibuprofen after 144 hours.
To our knowledge, this is the best dynamic kinetic resolution observed for ibuprofen in
terms of % conversion, ee, complexity, and cost. [26 and 27]
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The kinetics of this reaction was very interesting and two phased as shown in
Figure 2.10.

In the first part of the reaction, the hydrolysis rate depends on the

abundance of the (S)-methyl ibuprofen ester. In the second part, the hydrolysis reaction
is limited or depends on the reaction rate of racemization of the (R)-methyl ibuprofen
ester because little (S)-methyl ibuprofen ester is present. This kinetics was confirmed by
fitting a “consecutive reactions with a reversible step” model to the hydrolysis data.
Compared with all other reactions, the hydrolysis reaction at pH 9.8 with DMSO present
was almost twice as slow. The lipase functions in both aqueous and highly non-polar
solvents such as cyclohexane but is denatured by solvents of intermediate polarity such as
DMSO has been noted.
Although the dynamic kinetic resolution gave (S)-ibuprofen with an ee of 94 %
(97 % (S) to 3 % (R)-ibuprofen), racemic mixtures can be less soluble than pure
enantiomers. When crystallization was tried racemic ibuprofen crystallized and the (S)ibuprofen was still in solution (the best estimate being 99.7 % ee) and it was easily
isolated by evaporation.

This seems to contradict that a mixture of two different

molecules may have a stronger interaction than that of a pure compound but this
phenomena is often observed for racemic mixtures versus pure enantiomers. Combining
the dynamic kinetic resolution and crystallization steps, and considering that isolation of
ibuprofen from pills and forming its racemic methyl ester is also quantitative, the overall
conversion of (S)-ibuprofen from racemic ibuprofen pills, is 87.60 %, with the possibility
of recovering all other reagents.
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Using research laboratory prices, which are much more expensive than prices
available to industry, a mole of (S)-ibuprofen (206 g) could be synthesized for $112.
This would be 5 ¢ per pill from a pill that originally cost 1 ¢. Considering that $80 of this
cost per mole are reusable solvents and reagents, the price could go down to less than 2 ¢.
The final question is whether the pharmaceutical industry is willing to adopt this
orphan drug and if the consumer is willing to pay more for pure (S)-ibuprofen that works
three times as fast as racemic ibuprofen with less side effects.
Considering that in the United States, Gastro Intestinal (GI) complications due to
NSAIDs intake have been estimated to cause approximately 300,000 deaths and to cause
around 1,700,000 people to have been hospitalized at a cost of $38.8 billion, the price of
producing (S)-ibuprofen may be worth it, Figure 3.1.
In perspective, 300,000 people dying from NSAID GI bleeding is a greater
number than the number of dead (234,000) from the Revolutionary War, the War of
1812, the Mexican War, the Spanish-American War, World War I, the Korean War, the
Vietnam War, and the Persian Gulf Wars combined. [44]
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Figure 3.1 Estimated Yearly NSAID Deaths and Hositalization in the Last 25 Years

Given the long list of racemic profens (2-phenylpropionic acid, fenoprofen,
flurbiprofen, indoprofen, ketoprofen and pranaprofen) that should be converted to their
pharmacological active (S)-enantiomer, this successful research on the “Conversion of
Racemic Ibuprofen to (S)-Ibuprofen” should be extended to other profens. The major
obstacle of extending this methodology will be the solubility of other esters in the
aqueous hydrolysis step. For example, when the racemic propyl ibuprofen ester was
subjected to the same reaction conditions, only 56 % of the ester was hydrolyzed in 5
45

days. The ee of the ibuprofen was 93 %. Other ionic liquids and esters must be tested to
see if they will increase the miscibility of the esters with the aqueous media and make
this conversion faster and more general.

46

CHAPTER 4
MATERIAL, EQUIPMENT AND EXPERIMENTAL SECTION
4.1 Materials
Racemic ibuprofen (α-methyl-4-[isobutyl]phenylacetic acid) was isolated from
inexpensive commercial tablets (200 mg Member’s Mark, Sam’s Club). Candida rugosa
lipase (706 units / mg solid), methanol, propan-1-ol, butan-1-ol, pentan-1-ol, octan-1-ol,
decan-1-ol, p-toluenesulfonic acid, phenyl dimethyl chlorosilane, boric Acid, pyruvic
Acid, solute Si-Propylsulfonic Acid, isolute Si-TsOH, p-toluene sulfonyl chloride,
sodium hydroxide, sodium bicarbonate, tributyl amine, tripental amine, trioctyl amine,
diethyl amine and ethyl diisopropylamine were purchased from Aldrich Chemical
Company. Cyclohexane, hexanes and isopropanol were purchased from Mallinkcrodt
Reagents.

PL-HCO3 MP Resin, PL-OH MP Resin and PL-CO3 MP Resin were

purchased from Polymer Laboratories. Magnesium sulfate, potassium phosphate
monobasic and potassium phosphate dibasic were purchased from Spectrum Chemical
Company. All other chemicals and analytical grade reagents were from commercial
sources.
4.2 Equipment
4.2.1 Rotavapor
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A Rotavapor rotary evaporator (Figure 4.1) (BÜCHI, LABORATORLUMSTECHNIK AG, 70 Switzerland) was used to remove volatile solvents from reactions and
separations.

Figure 4.1 Rotavapor Used for Removes Solvents

4.2.2 High Performance Liquid Chromatography
High Performance Liquid Chromatography (HPLC) was performed with a
Chiracel OJ chiral column (Diacel Chemical Industries, LTD) Figure 4.2, a SpectraPhysics Spectra System P1500 gradient pump, UV2000 detector, and Winner for
Windows Software.

The mobile phase normally used was 95% hexanes and 5%

isopropanol by volume with helium solvent de-gassing. The flow rate was set to 1.00
mL/min. and the detector was set to a 256 nm wavelength, all at room temperature.
HPLC was used to monitor the esterification and hydrolysis reactions of ibuprofen.
Usually only 1.0 µL of analyte was used.
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Figure 4.2 Chiracel OJ, HPLC Chiral Column

4.2.3 Thin Layer Chromatography (TLC)
Silica gel 60 F254, size 2.5 cm x 7 cm TLC glass plates were used to monitor
reactions. A model UVGL-15 Mineralight® lamp, Multiband UV 254/366 nm (115 V,
60 Hz, 0.16 amps) lamp (Figure 4.3) was used to visualize TLC plates.

Figure 4.3 UV Lamp and TLC Plates Used to Monitor Reactions

4.2.4 Melting Points
Melting point measurements for starting materials and products were determined
with a Melt-Temp II (Laboratory Devices USA) melting point apparatus, Figure 4.4. A
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standard Celsius thermometer was inserted into the melting point apparatus without
calibration. A small amount of compound was packed into a melting point tube.

Figure 4.4 Melt-Temp II Laboratory Devices USA Equipment

4.2.5 Nuclear Magnetic Resonance (NMR)
NMR spectra were recorded with a Bruker Spectrospin Avance 300 Spectrometer
and JEOL 600 MHz. The solvent used for these experiments was deuterated chloroform
(CDCl3) relative to the internal tetramethylsilane standard (0.03 % v/v). All spectra
matched literature references.
4.2.6 Optical Polarimeter
The optical activities were measured using and Atago 5291 AP-300 Fully
Automatic Digital Polarimeter (Figure 4.5) at 22°C at 589 nm using samples with
concentrations of g/100 mL in ethanol.
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Figure 4.5 Atago 5291 AP-300 Fully Automatic Digital Polarimeter

4.2.7 ORION Model 420A Simple pH/mV/ORP/Temperature Benchtop Meter
The pH measurements were made using an Orion pH meter, Figure 4.6, by
introducing the pH electrode into the solution for a few seconds until the instrument was
stable on its reading.

Figure 4.6. Orion 420 A pH Meter
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4.3 Experimental
4.3.1 Extraction of Racemic Ibuprofen
Racemic ibuprofen was extracted from commercial tablets by braking and
suspending the tablets in acetone for 30 minutes in a beaker and filtering the insoluble
coating and filler. The filtrate solvent was removed under reduced pressure to recover
the amount of ibuprofen indicated on the bottle label quantitatively.
4.3.2 Racemic Ibuprofen Esters Synthesis
To a dry 125 mL round bottom flask was added 2.06g (10 mmol) of racemic
rbuprofen , 0.5 g sulfuric acid (H2SO4, 5 mmol) and 40 mL 990 mmol) of methanol. The
mixture was stirred at 40 ºC and monitored by chriral HPLC until reach the conversion
was greater than 99 %, which was about 5 hours. The reaction mixture was extracted
with 2 x 40 mL portions of hexane. The organic layers were separated and evaporated
under reduced pressure to determine the conversion . More alcohols were used for the
synthesis of larger esters but just in the methyl ester case, hexanes extraction was
sufficient to purify the product because methanol is insoluble in this solvent. In all other
cases, more hexanes (80 mL) and washings with water were necessary because larger
alcohols are amphiphilic or soluble in both polar and non-polar phases.
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4.3.3 Sodium Phosphate Buffer Preparation
A 2 M monobasic sodium phosphate solution was prepared in a 100 mL
volumetric flask. In a separate 100 mL volumetric flask, a 2 M dibasic sodium phosphate
solution was prepared.
To prepare the buffer solution at pH 5.3, to a 250 mL Erlenmeyer flask was added
90.5 mL of the monobasic solution and 9.5 mL on the dibasic solution.
For the preparation of the pH 7.2 buffer solution, to a 250 mL Erlenmeyer flask
was added 28 mL of the monobasic solution and 72 mL on the dibasic solution.
4.3.4 Sodium Bicarbonate/Sodium Hydroxide Buffer Preparation
A 0.5 M sodium bicarbonate solution was prepared in a 100 mL volumetric flask.
In a separate 100 mL volumetric flask a 1 M sodium hydroxide solution was prepared.
To prepare the pH 9.8 buffer solution, to a 250 mL Erlenmeyer flask was added
100 mL of the sodium bicarbonate solution and 15.2 mL of the sodium hydroxide
solution.
4.3.5 Addition of DMSO as Co-solvent to Increase the Enantioselectivity of Candida
rugosa Lipase
In a 25 mL round bottom flask; 1.1 g (5 mmol) of racemic methyl ibuprofen ester,
0.84 g of Candida rugosa lipase, 2 mL of DMSO, and 8 mL of pH 7.2 aqueous buffer
were placed. The mixture was stirred with a magnetic TeflonTM coated stir bar at 40 ºC.
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A control reaction was run at the same time without DMSO. Both reactions were
analyzed by chiral HPLC every 24 hours. The reaction was monitored for up to 172
hours.
4.3.6 Racemization of (R)-Methyl Ibuprofen Ester in 20 % DMSO/Buffer pH 9.8.
This reaction was performed at a 10 mL scale. In a typical reaction, to a 25 mL
dry round bottom flask were added 1.1 g (5 mmol) of enantiomeric eriched (R)-methyl
ibuprofen (as indicated by chiral HPLC), 2 mL of DMSO, and 8 mL of pH 9.8 aqueous
buffer. The reaction was stirred at 40 ºC. The mixture was analyzed by chiral HPLC
every 24 hours. The reaction was monitored for up to 172 hours.
4.3.7 Racemization of (R)-Ibuprofen at pH 5.3 Buffer
In order to determine whether racemization occurred to the ibuprofen ester,
ibuprofen or both at pH 5.3, a separated experiment was performed. In a 20 mL vial 0.50
g of (R)-ibuprofen 4 mL of pH 5.3 buffer and 1 mL of DMSO were placed. The reaction
was stirred and heated to 40 ºC for 5 days. Chiral HPLC was used for the daily
monitoring.
4.3.8 Kinetic Resolution of the Racemic Methyl Ibuprofen Ester
To a dry 125 mL round bottom flask was added 2.2 g (10 mmol) of racemic
methyl ibuprofen ester, 1.67 g of Candida rugosa lipase, and in three separate reactions
40 mL of aqueous buffers at pH 5.3, 7.2 and 9.8, respectively. The mixtures were stirred
at 45 ºC for 144 hours. The reactions were monitored at different time intervals. The
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basic samples were acidified to pH 5 with 1 molar HCl solution. When a reaction was
stopped, the reaction mixture was extracted with two 40 mL portions of hexanes. The
combined organic layers were dried with magnesium sulfate and the conversion of
methyl ibuprofen ester to ibuprofen was determined by a chiral HPLC analysis.
4.3.9 Dynamic Kinetic Resolution of Racemic Ibuprofen Ester
This reaction was run at different scales. In a dry 125 mL round bottom flask was
placed 2.20 g (10 mmol) of racemic methyl ibuprofen ester, 1.67 g of Candida rugosa
lipase, 8 mL of DMSO, and in three separate reactions 32 mL of aqueous buffers at pH
5.3, 7.2 and 9.8, respectively.

The mixtures were stirred at 40 ºC and monitored

(acidifying the basic samples with 1 molar HCl solution) by chiral HPLC for 144 hours.
The mixtures were extracted in two 40 mL portions of hexanes. The combined organic
layers were dried with magnesium sulfate and the conversions were determined by a
chiral HPLC analysis.
4.3.10 Crystallization of Enriched (S)-Ibuprofen to Enhance the Enantiomeric
Excess
In three different experiments 2.000 g of pulverized enantiomerically enriched (S)ibuprofen (ee = 94%) were added to 10 mL of methanol, ethanol, and isopropanol in a 25
mL round bottom flask. The flasks were placed in a water bath at 45 ºC and stirred with a
magnetic bar until the solution was clear; then the temperature of the water bath was
reduce to 35 ºC. When the flasks were cooled, some crystals of pulverized (S)-ibuprofen
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or racemic ibuprofen were added to the flask to act as nuclei (seeds). Then the flasks
were placed in a water bath at 25 ºC and the temperature was gradually reduced to 0 ºC in
about 6 hours. For maximum crystal recovery, the samples were allowed to stand at 0 ºC
in a refrigerator overnight.
The ibuprofen crystals were collected by vacuum filtration on a Buchner funnel
and dried at room temperature for further analysis. For ethanol and isopropanol, most of
the ibuprofen was recovered as filtered crystals with no enrichment.
For methanol, the solution was turbid and very little crystals formed. The filtrate
contained the desired enriched (S)-ibuprofen product, as indicated by chiral HPLC, and
was then evaporated to give solid product.

4.4 Other In Situ Racemization Attempts
4.4.1 Attempted In Situ Racemization of Ibuprofen with Organic Acids in
Cyclohexane
In a typical reaction, 2.06 g (10 mmol) of racemic ibuprofen was dissolved on 40
mL of cyclohexane, 6.66 g of Candida rugosa lipase, and 1.58 g (10 mmol) of decan-1-ol
and 0.026, 0.052, 0.103, 0.206, 0.412, 0.824 and 1.648 g of p-toluenesulfonic acid in
separate reactions. The reactions were monitored by chiral HPLC to determine the
racemization rate caused by the acid addition. The same procedure was followed using
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different acids or acid sources: p-toluenesulfonyl chloride, phenyl dimethyl chlorosilane,
boric acid, pyruvic acid, isolute Si-propylsulfonic acid, and isolute Si-TsOH.
4.4.2 Attempted In Situ Racemization of Ibuprofen with Organic Bases in
Cyclohexane
In a typical reaction, 2.06 g (10 mmol) of racemic ibuprofen was dissolved on 40
ml of cyclohexane, 6.66 g of Candida rugosa lipase and 1.58 g (10 mmol) of decan-1-ol
and 0.026, 0.052, 0.103, 0.206, 0.412, 0.824 and 1.648 g of trioctylamine in separate
reactions. The reaction were monitored by chiral HPLC to determine the racemization
rate caused by the acid addition. The same procedure was followed using different bases:
tripentylamine,

tributylamine,

diethylamine,

methyldiethylamine

and

ethyldisopropylamine.
4.4.3 Attempted Racemization of Methyl Ibuprofen Esters with Light
In a dry 125 mL Erlenmeyer flask was added 2.2 g (10 mmol) of racemic methyl
ibuprofen ester, 1.67 g of Candida rugosa lipase, and 40 mL of potassium phosphate
buffer solution at pH 7.2. A UVc lamp was inserted into the reaction to induce
photochemical reactions. The mixture was stirred at 45 ºC for 144 hours and monitored at
different time intervals. The reaction mixture was extracted with two 40 mL portions of
hexane. The combined organic layers were dried with anhydrous magnesium sulfate and
the conversion from racemic methyl ibuprofen ester to (S)-ibuprofen was determined by a
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chiral HPLC analysis. Some photochemical reactions were developed in a 7880
photochemical reactor from ACE photochemical reactors company.
4.4.4 Attempted Racemization of Ibuprofen in a Two-Phase Continuous Reactor
A two-phase reactor was designed to improve the esterification reaction with in
situ racemization of the unreacted (R)-ibuprofen. On the left side, to a 50 mL round
bottom flask was added 20 mL of distillated water, 3.33 g of Candida rugosa lipase and
1.03 g of racemic ibuprofen. The pH was adjusted to 8.6 by adding pulverized NaOH.
Cyclohexane and methanol 9/1 v/v were added to fill the flask. The left flask was
adjusted to 45 ºC with magnetic agitation and the right flask (product trap) was heated to
65 ºC to return the mixture of cyclohexane and methanol to the left flask. The samples
were taken from the right flask and analyzed by chiral HPLC at different interval times.
4.4.5 Attempted Racemization of Methyl Ibuprofen Esters with a Three-Phase
Membrane Separated Reactor
In a 250 mL round bottom flask, 80 mL potassium phosphate buffer solution at pH
7.2 and 13.12 g of Candida rugosa lipase were added to form the bottom aqueous phase.
80 mL of cyclohexane containing 4.4 g of racemic methyl ibuprofen ester were added
making the top phase of the two phase reaction. One gram of NaOH wrapped in either a
filter paper or Whatman Nucleopore filters was suspended by string in the organic phase.
The objective was the racemization of the unreacted (R)-methyl ibuprofen ester to
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increase the production of (S)-ibuprofen through the enantioselective enzymatic reaction
on the surface of the base pouch.
4.4.6 Attempted Acid Catalyzed Esterification, Racemization and Enantioselective
Hydrolysis in a Two Reactor System
Using two 50 mL round bottom flasks connected with a three way adapter two
different reactions were run. In a left flask 20 mmol of racemic ibuprofen, 1 g of
concentrate sulfuric acid were added and the rest of the volume was filled with a 10%
methanol-water solution ( the minimum methanol concentration to produce the esters). In
the right flask, 3.33 g of Candida rugosa lipase were placed and the flask was completely
filled with pH 7.2 sodium phosphate buffer solution. The two flask were connected by a
distillation adapter and the reactions were heated at 40 °C and stirred at a 100 rpm.
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Chemistry, University of Texas at El Paso
Dissertation: “Conversion of Racemic Ibuprofen to (S)-Ibuprofen”
The goal of this research was to develop the dynamic kinetic resolution
of (S)-ibuprofen from its racemate. This research is environmentally
benign and involved the use of enzymes as enantioselective catalysts in
organic and aqueous solvents, racemization and low temperatures.
Enzymes are the promising catalyst for the transformation and
production of chemicals due to the high efficiency and ability to catalyze
reactions such as hydrocarbon oxidation, desulfurization, dehydration,
esterification, hydrolysis, etc., enzymes are appealing for the
environmental chemistry (Green Chemistry).

2006 M. S.

Chemistry, University of Texas at El Paso
Thesis: “Commercial viable resolution of (S)-ibuprofen”
The goal of this research was to develop and environmentally friendly
kinetic resolution process for racemic ibuprofen; however the maximum
percent yield of the product obtained was 50 percent based on the
racemic starting substrate.

2002 B. S.

Chemical Engineering with emphasis on Foods, University of Chihuahua
Mexico
Thesis: “Design and Building of a Cooling Tower”
This research involved the design and building of a cooling tower to
reduce water waste and energy use in the cooling and pasteurization
process for cheese industry in the Chihuahuan desert.

PROFESSIONAL EXPERIENCE
2004 - 2010

Teaching Assistant of Organic Chemistry Laboratories in the Chemistry
Department at the University of Texas at El Paso. During my graduate
studies at UTEP, I worked as Teaching Assistant of the Organic
Chemistry Laboratories, lecturing for the pre-lab and monitoring the
laboratory sessions for chemistry major students.

2006 to 2008

Research Assistant in the Development of Materials World Modules and
a web page design for UG Science Courses ARMY. My research
assistantship requires that I develop and edit a scientific web page.
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http://materialsworld.utep.edu
May - June
2007

Sustainability and Green Chemistry Summer School, Pan-American
Advanced Studies Institute (PASI), Universidad Iberoamericana.
Mexico City, MEXICO. Organized by ACS Green Chemistry Institute. I
attended a 3-week summer course that brought together international
scientists to teach and interact with graduate students from around the
world. All the courses and laboratories were focused on Green Chemistry
and Sustainability.

May–Dec.
2005

Internship at the ExxonMobil Research and Engineering Company with
the Project "Preparation of Hybrid (Organic-Inorganic) Membranes for
Distillate Separation and Solvent Separation from Extraction”. I worked
in the Advanced Separation Division (Catalyst Technology), where
reactions involving different inorganic materials and organic membranes
were developed with the purpose of produce new hybrid materials with
superior chemical, thermal stability and selectivity. As result, we
obtained a membrane able to remove solvents from the extraction
mixture and a membrane able to upgrade the distillate quality to produce
diesel from FCC which reduced costs of the solvent recovery and diesel
separation.

1998 - 2002

During my bachelors on Chemical Engineering I made three internships
and the Community Service developing chemistry and chemical
engineering tasks as next:
Internship in DELPHI: Quality control and design of new products.
Internship in Harinas de Chihuahua: Quality control and analysis of final
product.
Community Service Chihuahua Health Department: Taking samples of
foods from restaurants in Chihuahua Mexico city for future
microbiological and physical analysis.
Internship in Cuproquim of Mexico: Quality Control.

CONFERENCES, CONGRESS AND ACHIEVEMENTS
October 2009

Oral Presentation at the SACNAS National Conference: “Improving the
Human Condition: Challenges for Interdisciplinary Science” in Dallas
Texas.
Publication: Karina Castillo, J.G. Parsons, David Chavez, Russell R.
Chianelli. Oxidation of Dibenzothiophene to Dibenzothiophene-sulfone
using Silica gel. Journal of Catalysis 268 (2009) 329–334
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June 2009

Oral Presentation at the 13th Annual Green Chemistry and Engineering
Conference in College Park MD. from June 22 to June 25, 2009.
Oral Presentation at the XI Congreso Mexicano de Catálisis in Ensenada
Baja California Mexico from June 2 to June 5, 2009.

April 2009

Publication: Chavez-Flores, D. and Salvador, J.M., Commercially
Viable Resolution of Ibuprofen. Biotechnol. J. 2009, 4, 1222–1224

October 2008

Poster Presentation at the SACNAS (Society for Advancement of
Chicanos and Native Americans in Science) National Conference:
“International Polar Year: Global change in Our Communities”, at Salt
Lake City, UT.

June 2008

Winner of the Poster presentation Award at the 12th Green Chemistry
and Engineering National Conference in Washington, DC. Organized by
ACS Green Chemistry Institute. At this conference, nearly 160 posters
were presented covering an array of issues, from Bio-based Materials &
Processes to Solvents and Solvent Systems, to green educational ideas.
Only two students received poster prizes ($1000), sponsored by Royal
Society of Chemistry and American Institute for Chemical Engineers
and Institute for Sustainability, one was awarded for my research
“Commercial Viable Resolution of (S)-Ibuprofen”.

April 2008

Oral Presentation at the I National Congress of Sustainable Chemistry
and II National Congress on Microscale Chemistry at the Autonomous
University of Yucatan, Mexico.

October 2007

Oral Presentation at the SACNAS National Conference: “Stretching the
Imagination to Support Leadership and Sustainability” in Kansas City
MO.

March 2007

Poster Presentation at ACS (American Chemical Society) National
Conference in Chicago Il.

October 2006

Poster Presentation at the SACNAS National Conference: “Science
Revolution in Minority Communities: What Progress Have We Made”
in Tampa Bay FL.

March 2006

Poster Presentation ACS (American Chemical Society) National
Conference in Atlanta GA.
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SKILLS PROFILE
Chemistry

Fourier Transform Infrared (FTIR) spectroscopy, Ultraviolet Visible
(UV-vis) spectroscopy, Flame Atomic Absorption Spectroscopy,
Chromatography techniques (GC, HPLC and HPLC-MS) and organic
molecules analysis by different techniques on NMR.

NMR
Maintenance

On the last 5 years I helped on the maintenance of the NMR instruments
(300 MHz Bruker and 600 MHz JEOL), Nitrogen and Helium fills.

Languages

I am bilingual and proficient in writing in both English and Spanish

Computer
Skills

Good Skills in data acquisition systems and software, database handling,
statistical data analysis, high proficiency in Microsoft Office, scientific
graphics, and publishing software
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